Cadrenal Therapeutics, Inc
Price
FilingsNewest: 8-K, Director or officer changeSep 29 →InsidersNo open-market buys. 2 insiders sold $585,500, 25 of 28 sales on a 10b5-1 plan.→HoldersVanguard 1.6%Geode 0.6%Vanguard Fiduciary Trust 0.3%→Financing →PeersClosest companies: VTGN, CMPX, PRLD→
From the filings
Figures
- Net income
- −$11.5Mlast 12 months
- Operating cash flow
- −$11.0Mlast 12 months
- Cash and equivalents
- $2.4Mat the last balance sheet
- Shares outstanding
- 3.1M shareson issue